# Pasireotide (SOM230): Multi-Receptor Somatostatin Analog — Research Profile
> Research Use Only (RUO). Pasireotide is discussed here strictly as a laboratory research reagent and pharmacological tool compound for in vitro and preclinical in vivo receptor studies. Nothing below is medical, veterinary, therapeutic, or dosing guidance, and none of it describes human or animal use outside controlled research settings.
Pasireotide (research designation SOM230) is a synthetic cyclohexapeptide that acts as a multi-receptor ("pan") somatostatin analog, engaging four of the five somatostatin receptor subtypes with a distinctive high affinity for SSTR5. In the laboratory, pasireotide is a key comparator reagent for dissecting somatostatin-receptor subtype pharmacology — particularly when contrasted against SSTR2-preferring analogs such as octreotide. This profile summarizes its molecular identity, receptor-binding profile, signaling behavior, structural context, and the experimental settings in which it appears, with every claim tied to a verifiable primary-literature citation.
For the SSTR2-preferring counterpart and the broader receptor family, see the Peptides.SO octreotide research profile and the somatostatin receptor biology research guide.
The Somatostatin System: Research Background
Somatostatin is an endogenous cyclic peptide existing in two bioactive forms, somatostatin-14 and somatostatin-28, generated from a common preprosomatostatin precursor. It acts as a broadly inhibitory signaling molecule across neuroendocrine, gastrointestinal, and central nervous tissues, and it exerts these effects through five G-protein-coupled receptor subtypes, SSTR1 through SSTR5. Native somatostatin engages all five subtypes with roughly comparable affinity but is degraded within minutes, which makes it impractical as a sustained laboratory reagent.
This pharmacological gap is exactly what synthetic analogs fill. The two dominant analog classes diverge in strategy: octreotide-class compounds narrow the engagement to SSTR2 (with some SSTR5) and add metabolic stability, while pasireotide retains breadth across four subtypes and re-weights the profile toward SSTR5. Having both a selective and a multi-receptor stable analog in hand lets researchers ask which subtype mediates a given somatostatin effect — a question native somatostatin cannot answer because it hits everything at once and disappears too quickly. The receptor subtypes also differ in tissue distribution, coupling efficiency, and trafficking, so subtype-resolved tools are essential rather than optional (Mol Biomed, 2026).
Molecular Identity
Pasireotide is a cyclic hexapeptide built on a constrained scaffold that differs structurally from the octreotide-class octapeptides. The cyclization and non-natural residue content rigidify the backbone into a conformation that broadens — rather than narrows — its somatostatin-receptor engagement. Where native somatostatin-14 binds all five subtypes (SSTR1–SSTR5) with comparable affinity but is rapidly degraded, and where octreotide trades breadth for SSTR2 selectivity and metabolic stability, pasireotide occupies a distinct niche: proteolytically stable like octreotide, yet broad across SSTR1, SSTR2, SSTR3, and especially SSTR5. This combination is what makes it a uniquely informative reagent in subtype-resolved pharmacology.
Receptor-Binding Profile
The defining research feature of pasireotide is its subtype affinity fingerprint. In radioligand and functional binding assays, pasireotide shows high affinity for SSTR5, substantial affinity for SSTR1, SSTR2, and SSTR3, and low affinity for SSTR4 — the inverse emphasis of octreotide, which is dominated by SSTR2. Functional profiling studies that systematically map analog activity across the receptor panel have reinforced that subtype engagement, not a single Ki value, determines the cellular response, and that SSTR2 versus SSTR5 weighting is the key axis separating these tool compounds (Mol Biomed, 2026).
This is most clearly illustrated in side-by-side reagent comparisons. Studies pairing octreotide and pasireotide in the same receptor-expressing cell systems show divergent downstream effects attributable to their different subtype weightings, making the two analogs a natural matched set for isolating SSTR2- versus SSTR5-mediated signaling (Cancers (Basel), 2021). For researchers, this means pasireotide is rarely used alone — its value emerges in panels where subtype contributions are being deconvolved.
Interpreting the affinity fingerprint requires methodological care. Reported subtype affinities vary with the expression system, the radioligand or functional readout chosen, and whether receptors are studied in isolation or as heteromeric assemblies, so absolute Ki values are less portable than the rank-order of engagement. The robust, reproducible observation across systems is the SSTR5-over-SSTR2 weighting that inverts the octreotide profile. When designing experiments, investigators therefore normalize within a single platform, report the assay format explicitly, and avoid cross-study Ki comparisons that ignore these context dependencies. Functional profiling that catalogs activity across the full SSTR panel under uniform conditions is the most reliable way to anchor pasireotide's place in the subtype landscape (Mol Biomed, 2026).
SSTR5 Pharmacology and Structural Context
Because SSTR5 is pasireotide's signature receptor, much of its mechanistic relevance is tied to advances in SSTR5 structural biology. Cryo-EM and structural studies have resolved SSTR5 bound with cyclic peptide ligands, revealing how the somatostatin pharmacophore engages the orthosteric pocket and how cyclic analogs are accommodated — a template directly applicable to interpreting pasireotide's binding mode (Acta Pharmacol Sin, 2024). More recent work has characterized the structural and functional basis of SSTR5 homodimerization, showing that receptor–receptor assembly itself shapes signaling output, an important consideration when using a SSTR5-preferring agonist as a probe (FASEB J, 2026).
SSTR5 expression and engagement have also been mapped in defined model systems, where pasireotide's role as an SSTR5-directed tool compound is examined against measured receptor levels (Pituitary, 2025). Together these datasets make SSTR5 one of the better-resolved somatostatin subtypes and anchor pasireotide's pharmacology in atomic-level structure.
Signaling Behavior
Somatostatin receptors are class A GPCRs that couple predominantly to Gi/o, inhibiting adenylyl cyclase to lower intracellular cAMP, while also modulating ion channels and engaging beta-arrestin-dependent pathways. Pasireotide, acting through its broad subtype profile, produces a composite signaling output reflecting the particular receptor complement of a given cell. Key experimental considerations include:
- •cAMP inhibition as the canonical functional readout, typically measured under forskolin stimulation.
- •Receptor internalization and beta-arrestin recruitment, which differ by subtype and by agonist; pasireotide and octreotide drive distinct trafficking behavior at shared receptors, a frequently studied contrast (Cancers (Basel), 2021).
- •Subtype-resolved controls, since a composite response cannot be attributed to any single receptor without parallel selective-agonist and knockdown comparisons.
The broader somatostatin-analog literature — including reviews of analog pharmacology across neoplastic and non-neoplastic research models — provides context for how multi-receptor versus selective engagement shapes these readouts (Int J Mol Sci, 2026).
Subtype Selectivity in the Research Panel
A core methodological theme is establishing which receptor subtype drives an observed effect. Because pasireotide is deliberately broad, it is most powerful when paired with subtype-selective comparators. Recent medicinal-chemistry work has produced selective tools such as SSTR3 full agonists, which allow researchers to isolate the SSTR3 component of a response and benchmark it against pasireotide's mixed engagement (Neuroendocrinology, 2025; Cancers (Basel), 2023). Fragment-merging and rational-design strategies have further generated dual-target molecules combining somatostatin-receptor activity with other GPCR pharmacology, expanding the toolkit for probing receptor crosstalk (J Med Chem, 2026). Receptor-expression profiling across model tissues also informs how subtype complement determines analog response, underscoring why selectivity must be re-established per system (J Clin Endocrinol Metab, 2026).
Handling and Assay Considerations for Researchers
- •Reconstitution: Handle pasireotide as a constrained cyclic peptide — see the peptide reconstitution guide and solubility and solvent selection guide.
- •Purity verification: Confirm identity and purity by HPLC and mass spectrometry; review peptide purity testing methods and how to read a certificate of analysis.
- •Assay design: Measure cAMP inhibition under forskolin challenge; run pasireotide alongside octreotide and subtype-selective agonists to deconvolve SSTR2 vs SSTR5 vs SSTR3 contributions; include SSTR-null controls.
- •Stability: The cyclohexapeptide backbone confers proteolytic stability superior to native somatostatin-14, supporting longer assay windows.
Related Somatostatin and GPCR Research
Pasireotide is best interpreted within the somatostatin-receptor family and the wider GPCR literature. Researchers cross-reference adjacent systems profiled on Peptides.SO:
- •Octreotide (SSTR2 analog) — the SSTR2-preferring counterpart and the single most useful matched comparator.
- •Somatostatin receptor biology research guide — receptor-family background and subtype distribution.
- •Cortistatin (CST-14) — a somatostatin-related neuropeptide sharing receptor engagement, useful for endogenous-ligand context.
To compare research reagents and suppliers, use the Peptides.SO supplier comparison tools and the how to evaluate peptide suppliers guide.
Frequently Asked Research Questions
What receptors does pasireotide target?
Pasireotide (SOM230) is a multi-receptor somatostatin analog with high affinity for SSTR5 and substantial affinity for SSTR1, SSTR2, and SSTR3, and low affinity for SSTR4 — a broader profile than the SSTR2-dominated octreotide (Mol Biomed, 2026).
How does it differ from octreotide as a reagent?
Octreotide is SSTR2-preferring; pasireotide is SSTR5-weighted and broad. Run in the same system, they produce divergent signaling and trafficking, which is why they are used together as a matched pair to isolate subtype contributions (Cancers (Basel), 2021).
Why is SSTR5 structural biology relevant?
SSTR5 is pasireotide's signature receptor. Structures of SSTR5 bound to cyclic peptides and analyses of SSTR5 homodimerization define how the ligand engages and how receptor assembly shapes signaling (Acta Pharmacol Sin, 2024; FASEB J, 2026).
What assay is standard?
cAMP inhibition under forskolin stimulation is the canonical functional readout for Gi/o-coupled somatostatin receptors, complemented by internalization and beta-arrestin assays and subtype-selective controls (Int J Mol Sci, 2026).
Summary
Pasireotide (SOM230) is a proteolytically stable, multi-receptor somatostatin analog distinguished by high SSTR5 affinity, making it an essential laboratory reagent for subtype-resolved somatostatin-receptor pharmacology — especially as the matched broad/SSTR5 counterpart to SSTR2-preferring octreotide. Its mechanism is best studied with cAMP-inhibition and trafficking assays across the SSTR panel, interpreted through the growing SSTR5 structural literature. As with all compounds profiled on Peptides.SO, pasireotide is presented for research use only, with no human, veterinary, therapeutic, or dosing application implied.
---
This article is provided for informational and research purposes only. Pasireotide is a research reagent intended for laboratory use only and is not approved for human or veterinary use in this context. Always follow institutional safety and compliance requirements.